General Information of Drug (ID: DM9V6YK)

Drug Name
PMID15055993C1a Drug Info
Synonyms GTPL6514; BDBM50131385
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9910222
TTD Drug ID
DM9V6YK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
DP-b99 DM97S10 Stroke 8B20 Phase 3 [3]
GS-5745 DMP8MDW Gastric adenocarcinoma 2B72 Phase 3 [4]
Andecaliximab DMLDB1X Gastric adenocarcinoma 2B72 Phase 3 [5]
BLZ-100 DMFKA4G Glioma 2A00.0 Phase 1/2 [6]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [7]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [8]
PMID29130358-Compound-Figure17(12) DMML4PA N. A. N. A. Patented [8]
PMID29130358-Compound-Figure17(10) DMVA15O N. A. N. A. Patented [8]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Matrix metalloproteinase-9 (MMP-9) TT6X50U MMP9_HUMAN Inhibitor [1]

References

1 Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. J Med Chem. 2004 Apr 8;47(8):1930-8.
2 Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
3 DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
4 National Cancer Institute Drug Dictionary (drug id 747683).
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
7 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
8 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.